Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PureTech’s Failure Leaves Long COVID Treatment Hopes Looking Thin

But Candidate Promising In IPF

Executive Summary

PureTech’s LYT-100 has failed to show benefit over placebo in long COVID, and raised doubts about how treatable the condition is – in contrast to the drug’s other potential use in idiopathic pulmonary fibrosis.

You may also be interested in...



CytoDyn In Damage-Control Mode (Again) With Clinical Holds For Leronlimab

Troubled leronlimab is placed on partial clinical hold in HIV, full clinical hold in COVID-19. While searching for a new CEO, CytoDyn tries to reassure investors about its business plan going forward.

Where To Start Tackling ‘Long Covid’? PureTech Pioneers Lung Drug Trial

PureTech is among the very first companies to attempt to treat long Covid and hopes its anti-fibrosis drug can aid patients’ recovery

Encouraging Biomarker Data Lift UniQure’s Huntington’s Disease Hopes

Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel